PDF file: 441-1106_vaccine_clinical_trials_safety_and_immunogenicity.pdf
OPQ ID: 441-1106
Session: 441
Question number: Q-1106
Sessional paper: Q-1106
Title: vaccine clinical trials safety and immunogenicity
Short description: 
Topic: vaccines
Identified concern: 
Keywords: 
Agencies: HC
Date asked: 2022-12-12
Date tabled: 
Submitted by: Mr. Carrie (Oshawa)
Reply by: Minister of Health
Responded by: Mr. van Koeverden
Pages: 7
Status: not processed
Alert: grey
Questions asked: 4
Questions answered: 4
Percent responded: 100%
Referenced sources: Canada.ca, World Health Organization, COVID-19 vaccines and treatments portal
Referenced links: https://bit.ly/3EH07IB, https://bit.ly/3GFvDHE, https://covid-vaccine.canada.ca/comirnaty/product-detailsModerna, https://covid-vaccine.canada.ca/covid-19-vaccine-moderna/productdetails, https://covidvaccine.canada.ca/covid-19-vaccine-moderna/product-details, https://covid-vaccine.canada.ca/comirnaty/product-details
Official link: https://www.google.com/search?q=Q-1106+ourcommons.ca
PDF URL: https://ivim.ca/foi/opq/r/441-1106_vaccine_clinical_trials_safety_and_immunogenicity.pdf
TXT URL: https://ivim.ca/foi/opq/r/441-1106.txt
Original filename: Q-1106 (Order) vaccine clinical trials safety and immunogenicity.pdf
Local source path: C:\Users\Dmitry\Documents\CODES\OPQ-App\data-raw\OPQ\ALL OPQ TO DATE\2022\Q-1106 (Order) vaccine clinical trials safety and immunogenicity.pdf
Machine extracted at: 2026-06-30 12:58:12

References / links:
- https://bit.ly/3EH07IB
- https://bit.ly/3GFvDHE
- https://covid-vaccine.canada.ca/comirnaty/product-detailsModerna
- https://covid-vaccine.canada.ca/covid-19-vaccine-moderna/productdetails(b
- https://covidvaccine.canada.ca/covid-19-vaccine-moderna/product-details(d
- https://covid-vaccine.canada.ca/comirnaty/product-details
- https://covidvaccine.canada.ca/covid-19-vaccine-moderna/product-details
- Canada.ca
- World Health Organization
- COVID-19 vaccines and treatments portal

Machine notes:
(none)

Question text preview:
With regard to the clinical trials conducted on COVID-19 vaccine safety, specifically those pertaining to the widely distributed vaccines by
Pfizer/BioNTech and Moderna that Health Canada reviewed: (a) were objections raised by the government when these vaccines were allowed to be given to the relatively healthy, unvaccinated trial participants mid-way into Phase 3 of the placebo-controlled clinical trials;
(b) if no action was taken in relation to (a), why not;
(c) of the safety data that could be analyzed, showing level-1 evidence of vaccine-induced harm (e.g. a risk increase in severe adverse events, more death, and after dissolution of the control group, more deaths in the experimental group), how were they used, if at all, when performing risk-benefit analyses; and (d) what specific information was used by the government to arrive at their position that there was more benefit to administering the COVID-19 vaccines to relatively healthy Canadians than risk?